Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.1652W HIGH $48.25
Volume
343.50 K
Value Traded
19.28 M
Short % Float
7.11%
-5.97%Week
-13.75%1 Month
-11.53%3 Month
-44.88%6 Month
-28.45%5 Year
+461.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.04 B
EPS (TTM)
-0.06
P/E Ratio
-
Ent. Value
1.32 B
Total Shares
48.73 M
Float Shares
46.16 M
Insiders
5.33%
Institutions
94.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AORT Catalyst Timeline
Dated clinical, regulatory and corporate events for Artivion, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artivion, Inc.
3Total events
1Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Trial Completion
Subscribe to view catalyst details
Past FDA Catalysts and PDUFA Decisions
How AORT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Artivion, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AORT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NEXUS Aortic Arch System | chronic dissection, aneurysm, or other arch disease | 2026-02-02 | survival rate: 94%; freedom from disabling stroke: 91%; free from reintervention due to endoleaks: 97%; no occurance of renal failure: true; one occurance of paraplegia: trueRead More | Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GREEN ANDREW MOfficer (SVP, Regulatory and Quality) | Sell | -11,480 40,160 held | $24.97 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AORT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.6 % (-50 %) | 39.04 M | 1.74 M | 6.11% ( 100.00 K) |
AORT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AORT ranks across every disease it competes in
Competitive Position is a premium feature
See how AORT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAORT News
AORTArtivion Reports Second Quarter 2026 Financial Results
Artivion, Inc. reported its financial results for the second quarter of 2026, highlighting an 11% revenue increase to $125.8 million. The company achieved FDA PMA approval for its AMDS Hybrid Prosthesis and completed the acquisition of Endospan Ltd. However, it also reported a net loss of $13.5 million, with a decrease in non-GAAP net income compared to the previous year. The company remains optimistic about its growth outlook for the remainder of 2026.
Read more →AORTArtivion to Participate in Upcoming Investor Conferences
Artivion, Inc. announced its participation in two upcoming investor conferences, highlighting its commitment to engaging with investors. The company will present at the Canaccord Genuity Annual Growth Conference on August 12, 2026, and will hold investor meetings at the Needham Virtual MedTech & Diagnostics Conference on August 11, 2026. These events reflect Artivion's ongoing efforts to connect with stakeholders and provide updates on its business.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion, Inc. has announced that it will release its second quarter 2026 financial results on August 6, 2026, after market close. A teleconference call will be held at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by CEO Pat Mackin. The event will be accessible via phone and webcast.
Read more →AORT▼ -5.2%on this news
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion, Inc. has received FDA approval for its AMDS Hybrid Prosthesis, aimed at treating acute DeBakey Type I aortic dissections. This approval allows hospitals to implant the device without the need for institutional review board approval, streamlining the process. Clinical data indicates a significant reduction in mortality and complications associated with the device, positioning Artivion for a substantial market opportunity.
Read more →AORTArtivion to Participate in the 2026 Truist Securities MedTech Conference
Artivion, Inc. will participate in the 2026 Truist Securities MedTech Conference on June 16, 2026. The event will feature a fireside chat at 1:00 p.m. ET, accessible via a live webcast on the company's website. Artivion specializes in medical devices for aortic diseases and has a diverse product range sold in over 100 countries.
Read more →AORTArtivion Completes Acquisition of Endospan Ltd.
Artivion, Inc. has successfully completed the acquisition of Endospan Ltd., enhancing its portfolio in the aortic arch market. The acquisition includes the NEXUS Aortic Arch System, which has received FDA approval for its premarket application. Artivion plans to utilize a $150 million loan for the acquisition costs, positioning itself as the sole company with a full suite of aortic arch solutions globally. This move is expected to strengthen Artivion's leadership in addressing aortic disease treatments.
Read more →AORTEndospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Artivion, Inc. has completed the acquisition of Endospan following the FDA's approval of the NEXUS® Aortic Arch System. This acquisition is anticipated to strengthen Artivion's portfolio in the aortic arch market. The FDA's PMA approval marks a significant milestone for the NEXUS® system, enhancing its market potential.
Read more →AORTArtivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
Artivion, Inc. announced its first quarter 2026 financial results, reporting an 18% increase in revenue and a net income of $1.4 million. The company received U.S. FDA PMA approval for the NEXUS Aortic Arch System and exercised an option to acquire Endospan for $135 million. Despite a strong start to the year, Artivion revised its 2026 revenue outlook downward, anticipating total revenues of $480 to $496 million. Additionally, the company expects negligible revenue from NEXUS sales until its launch in January 2027.
Read more →AORTArtivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter ...
Artivion, Inc. reported strong financial results for the first quarter of 2026, showcasing a revenue increase to $116.3 million and significant growth in adjusted EBITDA. The company announced the exercise of its option to acquire Endospan, enhancing its aortic arch solutions portfolio following FDA approval for the NEXUS Aortic Arch System. Despite a slight decrease in full-year revenue guidance, Artivion maintains confidence in its long-term strategies and growth potential in the aortic disease market.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Artivion, Inc. announced that it will release its first quarter 2026 financial results on May 7, 2026, after market close. A teleconference will follow at 4:30 p.m. ET, hosted by CEO Pat Mackin. Investors can access the live webcast and a replay on the company's website, along with the earnings press release.
Read more →AORT▲ +5.3%on this news
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
Artivion, Inc. has received FDA approval for the NEXUS Aortic Arch System, developed by Endospan. This system offers a minimally invasive treatment option for aortic arch disease, including chronic aortic dissections. The approval is based on promising trial data showing high survival rates and low complications. Artivion is now evaluating its option to acquire Endospan within 90 days.
Read more →AORTArtivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Artivion, Inc. will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026. The company's presentation will focus on its advancements in cardiac and vascular surgery, particularly related to aortic diseases. A live webcast will be available on their website, with an archived version accessible for 90 days.
Read more →AORT▼ -10%on this news
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
Artivion, Inc. reported strong financial results for Q4 and the full year 2025, with a 13% revenue growth and a 26% increase in adjusted EBITDA. The company highlighted significant growth in stent grafts and On-X products. Positive clinical trial data was presented at a major conference, reinforcing confidence in future growth. For 2026, Artivion anticipates revenue growth between 10% to 14%.
Read more →AORTArtivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion presented promising clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials at the 62nd Society of Thoracic Surgeons Annual Meeting. The NEXUS TRIOMPHE trial showed a 94% survival rate and 91% freedom from disabling stroke at one year. The AMDS PERSEVERE trial highlighted ongoing clinical benefits and positive aortic remodeling after two years.
Read more →AORTArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
Artivion, Inc. has announced that it will release its fourth quarter 2025 financial results on February 12, 2026, after market close. A teleconference and live webcast will follow at 4:30 p.m. ET, hosted by CEO Pat Mackin. Investors can access the earnings press release and participate in the Q&A session.
Read more →AORT▼ -5.5%on this news
Artivion Reports Third Quarter 2025 Financial Results
Artivion, Inc. reported strong financial results for Q3 2025, with total revenues reaching $113.4 million, an 18% increase year-over-year. The company achieved significant growth in stent grafts and On-X products, alongside a successful patient enrollment in the ARTIZEN trial. Artivion also presented favorable clinical data at a prominent conference and raised its revenue and EBITDA guidance for the year.
Read more →AORTArtivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Artivion, Inc. has treated the first patient in the ARTIZEN pivotal trial, which evaluates the Arcevo LSA Hybrid Stent Graft System for aortic arch pathologies. This multicenter trial aims to support the FDA application for Premarket Approval. The trial will follow 132 participants for up to five years, focusing on safety and efficacy outcomes.
Read more →About Artivion, Inc.
Headquarters1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
Founded1984
BIOPHARMAWATCH ELITE PLUS
Trade the next AORT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime